Application of exosome to diagnosis, treatment and prognosis evaluation of tumors

Abstract

The invention provides an application of an exosome to diagnosis, treatment and prognosis evaluation of tumors, particularly provides an application of the exosome to diagnosis and / or treatment and / orprognosis evaluation of lung cancer, and further provides a composition and / or kit. The composition and / or kit comprise exosome analysis agents and / or conditioning agents. The application is of greatrealistic significance for research of attacking, metastasis and control key molecule mechanisms of the lung cancer, improvement of treatment effects of the lung cancer and prognosis evaluation of lung cancer patients.

Description

technical field [0001] The present application relates to the field of tumor diagnosis and treatment, specifically, the application relates to the application of exosome modulators including inhibitors in the diagnosis and treatment of tumors such as lung cancer. Background technique [0002] Exosomes are nanoscale vesicle structures with a diameter of 40-130nm first discovered by Trams et al. in 1980, which contain a large number of proteins, nucleic acids and lipids, etc., and play a role in the transmission of intercellular material information. important role [11，12] . Compared with normal cells, tumor cells release more exosomes, and a series of protein and nucleic acid components contained in them play a key role in regulating the tumor microenvironment, promoting tumor invasion and directional metastasis [13，14] . In addition, studies have shown that high levels of exosomes produced by tumor cells are significantly correlated with poor prognosis of tumor patients. ...

AI Technical Summary

Problems solved by technology

At present, the treatment of NSCLC includes surgery, radiotherapy, chemotherapy, etc., but surgery is still the only possible cure for lung cancer. Less than half of the patients have the opportunity to receive radical surgery, and the 5-year survival rate after surgery is only 30-60%.

Although chemotherapy can improve the survival rate of NSCLC patients, the 5-year survival rate is only 15%; in general, the clinical prognosis of patients receiving postoperative adjuvant chemotherapy and advanced patients receiving radiotherapy and chemotherapy is not satisfactory [3，4]

Clinical data show that the invasion and metastasis of NSCLC are the key factors affecting the efficacy and survival of patients. However, due to the complex regulation mechanism of NSCLC metastasis, there is still a lack of effective predictive markers related to invasion and metastasis of lung cancer and possible targeted inhibition methods in clinical practice.

Images